ECSP024393A - SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH - Google Patents

SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH

Info

Publication number
ECSP024393A
ECSP024393A EC2002004393A ECSP024393A ECSP024393A EC SP024393 A ECSP024393 A EC SP024393A EC 2002004393 A EC2002004393 A EC 2002004393A EC SP024393 A ECSP024393 A EC SP024393A EC SP024393 A ECSP024393 A EC SP024393A
Authority
EC
Ecuador
Prior art keywords
treatment
compounds
formula
cellular growth
normal cellular
Prior art date
Application number
EC2002004393A
Other languages
Spanish (es)
Inventor
John Charles Kath
Joel Morris
Samit BHATTACHARYA
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ECSP024393A publication Critical patent/ECSP024393A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula I: Y a sales solvatos o profármacos farmacéuticamente aceptable de los mismos, en los cuales R1, R3, R4, R5, R11, m y p son tales como se han definido en la presente memoria. La invención se refiere también a métodos para tratar el crecimiento celular anormal en animales mamíferos administrando los compuestos de fórmula I, y a composiciones farmacéuticas para tratar los trastornos, que contienen los compuestos de la fórmula I. La invención se refiere también a métodos para preparar los compuestos de fórmula I.The invention relates to compounds of formula I: And to pharmaceutically acceptable solvate salts or prodrugs thereof, in which R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods for treating abnormal cell growth in mammalian animals by administering the compounds of formula I, and pharmaceutical compositions for treating disorders, which contain the compounds of formula I. The invention also relates to methods for preparing the compounds of formula I.

EC2002004393A 2000-06-22 2002-12-13 SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH ECSP024393A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21313600P 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ECSP024393A true ECSP024393A (en) 2003-02-06

Family

ID=22793862

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004393A ECSP024393A (en) 2000-06-22 2002-12-13 SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF NORMAL CELLULAR GROWTH

Country Status (42)

Country Link
US (2) US6890924B2 (en)
EP (1) EP1292591B1 (en)
JP (1) JP4044839B2 (en)
KR (1) KR100545537B1 (en)
CN (3) CN1437594A (en)
AP (1) AP2001002192A0 (en)
AR (1) AR032353A1 (en)
AT (1) ATE288431T1 (en)
AU (1) AU2001264159A1 (en)
BG (1) BG107269A (en)
BR (1) BR0111548A (en)
CA (1) CA2413424C (en)
CZ (1) CZ20023951A3 (en)
DE (1) DE60108754T2 (en)
DK (1) DK1292591T3 (en)
DZ (1) DZ3407A1 (en)
EA (1) EA005525B1 (en)
EC (1) ECSP024393A (en)
EE (1) EE200200710A (en)
ES (1) ES2236240T3 (en)
GE (1) GEP20063831B (en)
HR (1) HRP20021005A2 (en)
HU (1) HUP0301120A2 (en)
IL (1) IL152985A0 (en)
IS (1) IS6616A (en)
MA (1) MA26914A1 (en)
MX (1) MXPA02012870A (en)
MY (1) MY127181A (en)
NO (1) NO20026166D0 (en)
NZ (1) NZ522568A (en)
OA (1) OA12291A (en)
PA (1) PA8520301A1 (en)
PE (1) PE20020257A1 (en)
PL (1) PL359557A1 (en)
PT (1) PT1292591E (en)
SK (1) SK17102002A3 (en)
SV (1) SV2002000504A (en)
TN (1) TNSN01091A1 (en)
UA (1) UA73990C2 (en)
WO (1) WO2001098277A2 (en)
YU (1) YU95102A (en)
ZA (1) ZA200210231B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
RS49779B (en) * 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
CN1158266C (en) * 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 compound
CN1437594A (en) * 2000-06-22 2003-08-20 辉瑞产品公司 Substituted bicyclic derivatives for the treatment of abnormal cell growth
JP4285996B2 (en) * 2001-02-21 2009-06-24 田辺三菱製薬株式会社 Quinazoline derivatives
US20030144308A1 (en) * 2001-09-24 2003-07-31 Bauer Paul H. Fructose 1,6-bisphosphatase inhibitors
DE60223279T2 (en) * 2001-11-30 2008-05-29 Osi Pharmaceuticals, Inc. METHOD FOR THE PRODUCTION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ANOMALIC CELL GROWTH
IL161908A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
CN1608062A (en) 2001-12-12 2005-04-20 辉瑞产品公司 Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
NZ540092A (en) 2002-11-20 2007-06-29 Array Biopharma Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050085749A (en) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575936A1 (en) * 2002-12-19 2005-09-21 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use
EP1615910A1 (en) * 2003-04-09 2006-01-18 Pfizer Products Inc. Processes for the preparation of n-((((pyridinyloxy)-phenylamino)quinazolinyl)-allyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates
EP1636195A1 (en) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CA2531327A1 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
CN1822853A (en) * 2003-07-15 2006-08-23 加拿大国家研究委员会 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
JP4828421B2 (en) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド Quinazoline derivatives as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
SG135193A1 (en) * 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005044302A1 (en) * 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (en) 2004-02-03 2008-11-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
CN101014365B (en) 2004-07-16 2011-04-13 辉瑞产品公司 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
JPWO2006025490A1 (en) * 2004-09-01 2008-05-08 田辺三菱製薬株式会社 Molecular chaperone function regulator
WO2006071079A1 (en) * 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (en) 2004-12-29 2007-07-04 한미약품 주식회사 Quinazoline derivatives inhibiting the growth of cancer cell and preparation thereof
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
JP2008542356A (en) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク Bicyclic derivatives for the treatment of abnormal cell proliferation
SI2447283T1 (en) 2005-09-07 2015-12-31 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
DE602006021645D1 (en) 2005-11-15 2011-06-09 Array Biopharma Inc Process and intermediates for the preparation of N4-phenyl quinazoline-4-amine derivatives
GB0526552D0 (en) * 2005-12-29 2006-02-08 Morvus Technology Ltd New use
EA200802058A1 (en) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS
WO2008002039A1 (en) * 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662617C (en) * 2006-09-11 2014-11-18 Changgeng Qian Quinazoline based egfr inhibitors containing a zinc binding moiety
SG174772A1 (en) * 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
KR20090090336A (en) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 Fused Heterocyclic Compound
JP5377332B2 (en) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bicyclic heterocycles, drugs containing these compounds, their use and their preparation
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
WO2009098061A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
JPWO2009113560A1 (en) 2008-03-12 2011-07-21 武田薬品工業株式会社 Fused heterocyclic compounds
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
TW201920110A (en) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 Containing N-(4-{[6,7-bis(methoxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-di Pharmaceutical composition of methotrexate malate and use thereof
UA108618C2 (en) 2009-08-07 2015-05-25 APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
MD20140023A2 (en) 2011-09-22 2014-06-30 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN102872018B (en) * 2012-10-23 2015-07-15 广州市恒诺康医药科技有限公司 Tyrosine kinase irreversible inhibitor and preparation method and applications thereof
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
HRP20192056T1 (en) 2014-04-30 2020-02-21 Pfizer Inc. DICHETEROCYCLE DERIVATIVES BINDED TO CYCLOALKYL
KR101589632B1 (en) 2014-06-03 2016-02-01 한국과학기술연구원 6-Benzyloxyquinazolin-7-ylurea derivatives with an anticancer activity
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN115057861A (en) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
HRP20240293T1 (en) 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag QUINAZOLINE DERIVATIVES AS ANTI-TUMOR AGENTS
US20250206760A1 (en) * 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
EP4786473A1 (en) * 2023-09-27 2026-08-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ES2241324T3 (en) 1998-10-08 2005-10-16 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA.
JP3270834B2 (en) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1437594A (en) * 2000-06-22 2003-08-20 辉瑞产品公司 Substituted bicyclic derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
CN101348467A (en) 2009-01-21
HK1069576A1 (en) 2005-05-27
HUP0301120A2 (en) 2003-08-28
OA12291A (en) 2004-03-18
IL152985A0 (en) 2003-06-24
US6890924B2 (en) 2005-05-10
EE200200710A (en) 2004-06-15
CN1330640C (en) 2007-08-08
JP4044839B2 (en) 2008-02-06
NO20026166L (en) 2002-12-20
BG107269A (en) 2003-06-30
AR032353A1 (en) 2003-11-05
PE20020257A1 (en) 2002-04-08
DE60108754T2 (en) 2005-06-23
UA73990C2 (en) 2005-10-17
GEP20063831B (en) 2006-05-25
EP1292591B1 (en) 2005-02-02
US20050159435A1 (en) 2005-07-21
HRP20021005A2 (en) 2004-02-29
SK17102002A3 (en) 2004-04-06
MA26914A1 (en) 2004-12-20
SV2002000504A (en) 2002-10-24
MY127181A (en) 2006-11-30
WO2001098277A3 (en) 2002-06-13
KR100545537B1 (en) 2006-01-25
EA200201277A1 (en) 2003-06-26
DK1292591T3 (en) 2005-05-30
CN1437594A (en) 2003-08-20
JP2004501139A (en) 2004-01-15
ES2236240T3 (en) 2005-07-16
AP2001002192A0 (en) 2002-12-21
US20020169165A1 (en) 2002-11-14
ZA200210231B (en) 2004-02-12
US7332493B2 (en) 2008-02-19
MXPA02012870A (en) 2003-05-14
TNSN01091A1 (en) 2005-11-10
EP1292591A2 (en) 2003-03-19
WO2001098277A2 (en) 2001-12-27
CN1576275A (en) 2005-02-09
PL359557A1 (en) 2004-08-23
BR0111548A (en) 2003-05-06
ATE288431T1 (en) 2005-02-15
IS6616A (en) 2002-11-14
PA8520301A1 (en) 2003-06-30
PT1292591E (en) 2005-06-30
CZ20023951A3 (en) 2004-01-14
EA005525B1 (en) 2005-04-28
DZ3407A1 (en) 2001-12-27
CA2413424A1 (en) 2001-12-27
KR20030016303A (en) 2003-02-26
YU95102A (en) 2005-11-28
AU2001264159A1 (en) 2002-01-02
DE60108754D1 (en) 2005-03-10
NZ522568A (en) 2004-12-24
NO20026166D0 (en) 2002-12-20
CA2413424C (en) 2007-10-02

Similar Documents

Publication Publication Date Title
SV2002000504A (en) REPLACED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH REF.PC10760 / 20205 / BB
ECSP055633A (en) NEW BENZOIMIDAZOLUTILES DERIVATIVES AS ANTIPROLIFERATIVE ANGENTS
UY28135A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8487601A1 (en) USEFUL SUBSTITUTED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER
AR046297A1 (en) DPP INHIBITORS - IV METHODS TO PREPARE THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AS ACTIVE AGENTS
CU23132A3 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
PA8490601A1 (en) QUINOLIN-2-ONA DERIVATIVES SUBSTITUTED WITH HETEROARILO USEFUL AS ANTICANCERIGEN AGENTS.
UY28132A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
DK1697370T3 (en) Azabicyclic heterocyclic compounds as cannabinoid receptor modulators
UY27685A1 (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE
UY28357A1 (en) DERIVATIVES OF BENZIMIDAZOL, COMPOSITIONS THAT CONTAIN THEM, PREPARATION OF THE SAME AND ITS USES
DOP2002000519A (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
PA8474401A1 (en) 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN
UY26785A1 (en) SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UY27557A1 (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH.
DOP2003000786A (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH.
UY28131A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
ECSP993260A (en) USEFUL SUBSTITUTE BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER
BRPI0515835A (en) tetraline and indane derivatives and their uses
ECSP993117A (en) DERIVATIVES OF QUINOLIN -2 - ONA USEFUL AS AGENTS AGAINST CANCER
ECSP003347A (en) QUINOLIN DERIVATIVES - 2- ONA SUBSTITUTED WITH HETEROARILO USEFUL AS ANTI-BANERIGINAL AGENTS
CR6833A (en) SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
GT200100120A (en) REPLACED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
ECSP003793A (en) NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS